| Symbol | EDIT |
|---|---|
| Name | EDITAS MEDICINE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11 HURLEY STREET, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 401-9000 |
| Fax | — |
| — | |
| Website | https://www.editasmedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001650664 |
| Description | Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The companys only operating segment is developing and commercializing genome editing technology. Additional info from NASDAQ: |
(99% Neutral) EDITAS MEDICINE, INC. (EDIT) Reports Q2 2026 Financial Results
Read moreNew Form DEFA14A - Editas Medicine, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001650664-26-000038 <b>Size:</b> 490 KB
Read moreNew Form DEF 14A - Editas Medicine, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001650664-26-000037 <b>Size:</b> 7 MB
Read moreEditas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Read moreEditas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Read moreNew Form SCHEDULE 13G/A - Editas Medicine, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001154 <b>Size:</b> 7 KB
Read more(99% Neutral) EDITAS MEDICINE, INC. (EDIT) Reports Q1 2026 Financial Results
Read moreEditas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Read moreDirector O'Neill Gilmore Neil 🔴 sold 5.4K shares of Editas Medicine, Inc. (EDIT) at $2.02 Transaction Date: Mar 03, 2026 | Filing ID: 000009
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06363760 | A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfu… | — | Sickle Cell Disease | Enrolling_By_Invitation | 2024-06-17 | 2040-08-01 | ClinicalTrials.gov |
| NCT05444894 | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participan… | Phase1 | Transfusion Dependent Beta Thalassemia | Active_Not_Recruiting | 2022-04-29 | 2025-12-01 | ClinicalTrials.gov |
| NCT04853576 | A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Sev… | Phase1 | Sickle Cell Disease | Active_Not_Recruiting | 2021-05-04 | 2025-08-01 | ClinicalTrials.gov |
| NCT03872479 | Single Ascending Dose Study in Participants With LCA10 | Phase1 | Leber Congenital Amaurosis 10 | Unknown | 2019-09-26 | 2025-05-23 | ClinicalTrials.gov |
| NCT03396042 | Natural History Study of CEP290-Related Retinal Degeneration | — | Blindness | Completed | 2017-12-17 | 2022-05-06 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EDIT-301 | Other | Phase PHASE1 | Sickle Cell Disease | ACTIVE_NOT_RECRUITING | NCT04853576 |
| EDIT-101 | Other | Phase PHASE1 | Leber Congenital Amaurosis 10 | UNKNOWN | NCT03872479 |
| Safety and efficacy assessments | Other | Preclinical | Sickle Cell Disease | ENROLLING_BY_INVITATION | NCT06363760 |
| EDIT-301 | Other | Phase PHASE1 | Transfusion Dependent Beta Thalassemia | ACTIVE_NOT_RECRUITING | NCT05444894 |
| Safety and efficacy assessments | OTHER | Preclinical | Sickle Cell Disease | ENROLLING_BY_INVITATION | NCT06363760 |
| EDIT-301 | GENETIC | Phase PHASE1 | Transfusion Dependent Beta Thalassemia | ACTIVE_NOT_RECRUITING | NCT05444894 |
| EDIT-101 | DRUG | Phase PHASE1 | Leber Congenital Amaurosis 10 | UNKNOWN | NCT03872479 |